ImmunityBio stock dips despite Anktiva trial validation, FDA ad warning, and bullish analyst targets amid strong year-to-date gains.
Importance Rank:
1
ImmunityBio stock dips despite Anktiva trial validation, FDA ad warning, and bullish analyst targets amid strong year-to-date gains.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.